Galena Biopharma (GALE) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Galena Biopharma Reports First Quarter 2015 Financial Results
May 7, 2015 4:15 PM EDTCompleted enrollment in the NeuVax Phase 3 PRESENT breast cancer immunotherapy clinical trial Commercial programs continue on track Abstral® (fentanyl) Sublingual Tablets achieve net revenue of $2.8 million; full year 2015 net revenue guidance reiterated at $15-$18 million Zuplenz® (ondansetron) Oral Soluble Film product launch targeted for July Webcast and conference call scheduled for today at 2:00 p.m. P.T. / 5:00 p.m. E.T.
PORTLAND, Ore., May 7, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq: GALE), a biopharmaceutical company... More
